Reviewing Pressure BioSciences (OTCMKTS:PBIO) & Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG) and Pressure BioSciences (OTCMKTS:PBIO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Intuitive Surgical and Pressure BioSciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06 billion	13.70	$2.86 billion	$8.73	44.71
Pressure BioSciences	$1.98 million	0.01	-$29.31 million	($0.96)	-0.00

Intuitive Surgical has higher revenue and earnings than Pressure BioSciences. Pressure BioSciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intuitive Surgical has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of 5.8, meaning that its stock price is 480% more volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Pressure BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.45%	16.91%	14.83%
Pressure BioSciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Intuitive Surgical and Pressure BioSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1	8	22	0	2.68
Pressure BioSciences	0	0	0	0	0.00

Intuitive Surgical currently has a consensus target price of $508.68, suggesting a potential upside of 30.32%. Given Intuitive Surgical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Intuitive Surgical is more favorable than Pressure BioSciences.

Institutional & Insider Ownership

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 10.8% of Pressure BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Intuitive Surgical beats Pressure BioSciences on 12 of the 14 factors compared between the two stocks.

About Intuitive Surgical

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.